| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | F A Fonseca | |
| C Cercato | |||
| P2860 | cites work | Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease | Q24601951 |
| A core gut microbiome in obese and lean twins | Q24649648 | ||
| Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives | Q26746239 | ||
| Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and β-Cell Dysfunction | Q26800081 | ||
| Microbial ecology: human gut microbes associated with obesity | Q27861004 | ||
| Perivascular adipose tissue and coronary vascular disease | Q28390524 | ||
| Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome | Q29617424 | ||
| Drug treatments for obesity: orlistat, sibutramine, and rimonabant. | Q30359088 | ||
| Impact of obesity on cardiovascular disease. | Q30371908 | ||
| The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss | Q30596646 | ||
| New drug therapies for the treatment of overweight and obese patients | Q33652878 | ||
| Mechanisms of inflammatory responses in obese adipose tissue | Q33699810 | ||
| Ghrelin: much more than a hunger hormone | Q33725885 | ||
| The incretin system and cardiometabolic disease | Q33776092 | ||
| Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction | Q33839167 | ||
| Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects | Q34136304 | ||
| Metabolically healthy obesity: definitions, determinants and clinical implications | Q34362808 | ||
| GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-cont | Q34511743 | ||
| Obesity: pathophysiology and intervention | Q34578124 | ||
| Leptin mediates the increase in blood pressure associated with obesity | Q34655110 | ||
| [Cytokines, endothelial dysfunction, and insulin resistance] | Q83969553 | ||
| Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial | Q88873186 | ||
| Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA | Q89052824 | ||
| Adipokine dysregulation and adipose tissue inflammation in human obesity | Q89564366 | ||
| Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients | Q91144393 | ||
| State-of-the-art review article. Atherosclerosis affecting fat: What can we learn by imaging perivascular adipose tissue? | Q92884165 | ||
| Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome | Q35063234 | ||
| Evaluation of efficacy and safety of orlistat in obese patients | Q35073399 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| Adiponectin in cardiovascular inflammation and obesity | Q35219362 | ||
| Relationships between obesity and cardiovascular diseases in four southern states and Colorado | Q35647240 | ||
| Leptin and hypertension in obesity | Q36012983 | ||
| Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance | Q36037520 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph | Q36354637 | ||
| Epidemiology, trends, and morbidities of obesity and the metabolic syndrome | Q36452547 | ||
| Obesity and inflammation: epidemiology, risk factors, and markers of inflammation | Q36838201 | ||
| The Epidemiology of Obesity: A Big Picture | Q36877310 | ||
| Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? | Q37022560 | ||
| Naltrexone extended-release plus bupropion extended-release for treatment of obesity | Q37194488 | ||
| Obesity: effects on cardiovascular disease and its diagnosis | Q37319154 | ||
| JNK at the crossroad of obesity, insulin resistance, and cell stress response. | Q37613827 | ||
| Obesity and coronary artery disease: role of vascular inflammation | Q37739248 | ||
| New and emerging regulators of intestinal lipoprotein secretion | Q38188724 | ||
| Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. | Q38207128 | ||
| The role of adipose tissue immune cells in obesity and low-grade inflammation. | Q38227543 | ||
| Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial | Q38395083 | ||
| Relationship between adiponectin, obesity and insulin resistance | Q38440408 | ||
| Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study | Q38449189 | ||
| The role of infiltrating immune cells in dysfunctional adipose tissue. | Q38637700 | ||
| C-reactive protein in Brazilian adolescents: distribution and association with metabolic syndrome in ERICA survey | Q38767550 | ||
| The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond | Q38820260 | ||
| Inflammatory activity of adipose tissue. | Q42339254 | ||
| Recent progress and novel perspectives on obesity pharmacotherapy | Q42881681 | ||
| The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review. | Q43375937 | ||
| The impact of obesity on subclinical coronary atherosclerosis according to the risk of cardiovascular disease. | Q45011195 | ||
| Randomized trial of lifestyle modification and pharmacotherapy for obesity | Q46807914 | ||
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial | Q47233232 | ||
| A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management | Q47377383 | ||
| Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials | Q47918439 | ||
| Obesity Pathogenesis: An Endocrine Society Scientific Statement | Q50130740 | ||
| Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies | Q57111078 | ||
| Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) | Q57182634 | ||
| Which measures of obesity best predict cardiovascular risk? | Q81783528 | ||
| P304 | page(s) | 74 | |
| P577 | publication date | 2019-08-28 | |
| P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
| P1476 | title | Cardiovascular risk and obesity | |
| P478 | volume | 11 |
| Q89540094 | Digital interventions in the treatment of cardiovascular risk factors and atherosclerotic vascular disease |
| Q89919980 | Is Abdominal Fat Distribution Associated with Chronotype in Adults Independently of Lifestyle Factors? |
| Q98197432 | Visceral adipose tissue in patients with COVID-19: risk stratification for severity |
Search more.